Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

  • Torrano, Verónica
  • Valcarcel Jimenez, Lorea
  • Cortazar, Ana Rosa
  • Liu, Xiaojing
  • Urosevic, Jelena
  • Castillo Martin, Mireia
  • Fernández Ruiz, Sonia
  • Morciano, Giampaolo
  • Caro Maldonado, Alfredo
  • Guiu, Marc
  • Zúñiga García, Patricia
  • Graupera i Garcia-Milà, Mariona
  • Bellmunt i Tarragó, Anna
  • Pandya, Pahini
  • Lorente, Mar
  • Martín-Martín, Natalia
  • Sutherland, James David
  • Sánchez Mosquera, Pilar
  • Bozal Basterra, Laura
  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Berenguer Llergo, Antoni
  • Embade, Nieves
  • Ugalde Olano, Aitziber
  • Lacasa-Viscasillas, Isabel
  • Loizaga Iriarte, Ana
  • Unda Urzaiz, Miguel
  • Schultz, Nikolaus
  • Aransay, Ana M.
  • Sanz Moreno, Victoria
  • Barrio, Rosa
  • Velasco, Guillermo
  • Pinton, Paolo
  • Cordon Cardo, Carlos
  • Locasale, Jason W.
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcarcel Jimenez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The immunosuppressive effect of the tick protein, Salp15, is long-lasting and persists in a murine model of hematopoietic transplant

  • Tomás-Cortázar, Julen
  • Martín-Ruiz, Itziar
  • Barriales, Diego
  • Pascual-Itoiz, Miguel Ángel
  • Gutiérrez de Juan, Virginia
  • Caro-Maldonado, Alfredo
  • Merino, Nekane
  • Marina, Alberto
  • Blanco, Francisco J.
  • Flores, Juana María
  • Sutherland, James D.
  • Barrio, Rosa
  • Rojas, Adriana
  • Martínez-Chantar, María Luz
  • Carracedo, Arkaitz
  • Simó, Carolina
  • García-Cañas, Virginia
  • Abecia, Leticia
  • Lavín, José Luis
  • Aransay, Ana M.
  • Rodríguez, Héctor
  • Anguita, Juan
Salp15, a salivary protein of Ixodes ticks, inhibits the activation of naïve CD4 T cells. Treatment with Salp15 results in the inhibition of early signaling events and the production of the autocrine growth factor, interleukin-2. The fate of the CD4 T cells activated in the presence of Salp15 or its long-term effects are, however, unknown. We now show that Salp15 binding to CD4 is persistent and induces a long-lasting immunomodulatory effect. The activity of Salp15 results in sustained diminished cross-antigenic antibody production even after interruption of the treatment with the protein. Transcriptionally, the salivary protein provokes an acute effect that includes known activation markers, such as Il2 or Cd44, and that fades over time. The long-term effects exerted by Salp15 do not involve the induction of either anergy traits nor increased populations of regulatory T cells. Similarly, the treatment with Salp15 does not result in B cell anergy or the generation of myeloid suppressor cells. However, Salp15 induces the increased expression of the ectoenzyme, CD73, in regulatory T cells and increased production of adenosine. Our study provides a profound characterization of the immunomodulatory activity of Salp15 and suggests that its long-term effects are due to the specific regulation of CD73. Introduction, Supported by grants from the Department of Education of the Basque Government (PI2013-49 to JA and PI2012-42 to RB). JA is funded by the European Union (Grant Agreement number 602272). AMA and JLL’s work was supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia and the CIBERehd Network. The work of AC is supported by a Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek), ISCIII (PI13/00031), FERO VIII Fellowship, the BBVA foundation, MINECO (SAF2016-79381-R) and the European Research Council Starting Grant (336343). CIBERonc was co-funded with FEDER funds. AC-M was funded by a Juan de la Cierva program award and the European Union MSCA program (CIG 660191). RB was funded by MINECO grants BFU2011-25986 and BFU2014-52282-P and the Consolider Program (BFU2014-57703-REDC). FJB was funded by a MINECO grant (CTQ2014-56966-R). D.B. is funded by a MINECO FPI fellowship. We thank the MINECO for the Severo Ochoa Excellence accreditation (SEV-2016-0644)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

  • Torrano, Verónica
  • Valcarcel Jimenez, Lorea
  • Cortazar, Ana Rosa
  • Liu, Xiaojing
  • Urosevic, Jelena
  • Castillo Martin, Mireia
  • Fernández Ruiz, Sonia
  • Morciano, Giampaolo
  • Caro Maldonado, Alfredo
  • Guiu, Marc
  • Zúñiga García, Patricia
  • Graupera i Garcia-Milà, Mariona
  • Bellmunt i Tarragó, Anna
  • Pandya, Pahini
  • Lorente, Mar
  • Martín-Martín, Natalia
  • Sutherland, James David
  • Sánchez Mosquera, Pilar
  • Bozal Basterra, Laura
  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Berenguer Llergo, Antoni
  • Embade, Nieves
  • Ugalde Olano, Aitziber
  • Lacasa-Viscasillas, Isabel
  • Loizaga Iriarte, Ana
  • Unda Urzaiz, Miguel
  • Schultz, Nikolaus
  • Aransay, Ana M.
  • Sanz Moreno, Victoria
  • Barrio, Rosa
  • Velasco, Guillermo
  • Pinton, Paolo
  • Cordon Cardo, Carlos
  • Locasale, Jason W.
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcárcel-Jiménez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Camacho, Laura
  • Zabala-Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola, Kepa
  • Arreal, Leire
  • Valcarcel-Jimenez, Lorea
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Flores, Juana M.|||0000-0002-7995-4426
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Zúñiga-García, Patricia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Olivan, Mireia|||0000-0002-8464-0827
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.